Mutation Analysis of Radioresistant Early-Stage Cervical Cancer

Radiotherapy is a definitive treatment for early-stage cervical cancer; however, a subset of this disease recurs locally, necessitating establishment of predictive biomarkers and treatment strategies. To address this issue, we performed gene panel-based sequencing of 18 stage IB cervical cancers treated with definitive radiotherapy, including two cases of local recurrence, followed by in vitro and in silico analyses. Simultaneous mutations in KRAS and SMAD4 (KRAS(mt)/SMAD4(mt)) were detected only in a local recurrence case, indicating potential association of this mutation signature with radioresistance. In isogenic cell-based experiments, a combination of activating KRAS mutation and SMAD4 deficiency led to X-ray resistance, whereas either of these factors alone did not. Analysis of genomic data from 55,308 cancers showed a significant trend toward cooccurrence of mutations in KRAS and SMAD4. Gene Set Enrichment Analysis of the Cancer Cell Line Encyclopedia dataset suggested upregulation of the pathways involved in epithelial mesenchymal transition and inflammatory responses in KRAS(mt)/SMAD4(mt) cancer cells. Notably, irradiation with therapeutic carbon ions led to robust killing of X-ray-resistant KRAS(mt)/SMAD4(mt) cancer cells. These data indicate that the KRAS(mt)/SMAD4(mt) signature is a potential predictor of radioresistance, and that carbon ion radiotherapy is a potential option to treat early-stage cervical cancers with the KRAS(mt)/SMAD4(mt) signature.

Automated summary

Simultaneous mutations in KRAS and SMAD4 may be associated with radioresistance in cervical cancer, and carbon ion radiotherapy could be a potential treatment option for these cases.